The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty

Journal of the American College of Cardiology

Volumn 17, Issue 6 SUPPL. 2, 1991, Pages 77-88

  Ip, John H ^a   Fuster, Valentin ^a   Israel, Douglas ^a   Badimon, Lina ^a   Badimon, Juan ^a   Chesebro, James H ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; FISH OIL; HEPARIN; OMEGA 3 FATTY ACID; TICLOPIDINE; WARFARIN;

CONFERENCE PAPER; CORONARY ARTERY DILATATION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMAL; BLOOD PLATELETS; CORONARY DISEASE; CORONARY VESSELS; FIBRINOLYTIC AGENTS; HEMODYNAMICS; HUMAN; HYPERPLASIA; MUSCLE, SMOOTH, VASCULAR; RECURRENCE; THROMBIN; TIME FACTORS;

EID: 0025903839     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(91)90942-3     Document Type: Article

References (107)

1. Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasly
2. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation
3. “Crackers, breakers, stretchers, drillers, scrapes, havers, burners, welders and melters”: the future treatment of atherosclerotic coronary artery disease? A clinical-morphologic assessment
4. Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study
5. Change in diameter of coronary artery segments adjacent to stenosis after percutaneous transluminal coronary angioplasty: failure of percent diameter stenosis measurement to reflect morphologic changes induced by balloon dilation
6. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasly
7. Changes of angioscopic macromorphology following coronary angioplasty (abstr)
8. Arterial changes after percutaneous coronary angioplasty: results at autopsy
9. Pathological changes induced by repeated percutaneous transluminal coronary angioplasty
10. Morphology after PTCA in human beings
11. Transluminal coronary angioplasty and early restenosis: fibrocellular occlusion after wall laceration
12. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after perculaneous transluminal coronary angioplasty
13. The spectrum of pathology associated with percutaneous transluminal coronary angioplasty during acute myocardial infarction
14. Plaque morphology and pathologic changes in arteries from patients dying after coronary balloon angioplasty
15. Pathology of percutaneous transluminal coronary angioplasty complications (abstr)
16. Ultrastructural study of proliferating and migrating smooth muscle cells at the site of percutaneous transluminal coronary angioplasty as an explanation for restenosis (abstr)
17. Effects of percutaneous transluminal coronary angioplasty on atherosclerotic plaques and relation of plaque composition and arterial size to outcome
18. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1978
19. Residual thrombus is more thrombogenic than severele damaged vessel wall (abstr)
20. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
21. Insights into the pathogenesis of acute ischemic syndromes
22. Post-angioplasty occlusion and restenosis: mechanism and prevention by pharmacological therapy
23. Restenosis after coronary angioplasty: Potential biologic determinants and role of intimal hyperplasia
24. Balloon angioplasly in natural history of the pathophysiological response to injury in a pig model
25. New nonisotopic in-vivo technique of quantitating cellular proliferation in arterial media and intima (abstr)
26. Significance of quiescent smooth muscle cell migration in the injured rat carotid artery
27. Identification and distribution of fibrinogen, fibrin and fibrin degradation products in atherosclerosis: use of monoclonal antibody
28. Fate of fibrinogen in human arterial intima
29. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: effects of different stenosis on thrombus growth
30. Influence of arterial damage and wall shear rate on platelet deposition: ex vivo study in a swine model
31. Mechanism of arterial thrombosis in non-parallel streamlines: platelet thrombi grow at the apex of stenotic severely injured vessel wall: experimental study in the pig model
32. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction
33. Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction
34. Restenosis after successful coronary angioplasty in patients with single vessel disease
35. Substances affecting adult tissue in vitro part II A growth inhibitor in adult tissue
36. Suppression by heparin of smooth muscle cell proliferation in injured arteries
37. Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and nonanticoagulant heparin
38. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth
39. Endothelial regeneration: V. Inhibition of endothelial regrowth in arteries of rat and rabbit
40. Endothelial regeneration: II. Restitution of endothelial continuity
41. Smooth muscle phenotypic changes in arterial wall homeostasis: implication for the pathogenesis of atherosclerosis
42. Purification and binding properties of human platelet faclor-4
43. An endothelial cell-derived growth factor
44. Regulation of production of a platelet derived growth factor-like protein by cultured bovine aortic endothelial cells
45. Production of platelet-derived growth factor-like molecule by cultured arterial smooth muscle cells accompanied by proliferation after arterial injury
46. Effect of balloon inflation on smooth muscle cell proliferation in the porcine carotid artery (abstr)
47. Regulation of smooth muscle cell growth in injured artery
48. Adhesion and aggregation: morphological demonstration and quantification in vivo and in vitro
49. Vascular permeation of platelet faclor-4 after endothelial injury
50. The platelet derived growth factor
51. Liberation of the immunoreactive somatomedin C from its binding proteins by proleolylic enzymes and heparin
52. Cellular transformation by coordinate action by three peptide growth factors from human platelets
53. Platelet derived growth factor mRN A detection in human atherosclerotic plaques by in-situ hybridization
54. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbit
55. Evolution and progression of atherosclerotic lesions in coronary arteries of children and adults
56. Localization of atherosclerotic lesions in the bifurcation of Ihe main left coronary artery
57. Distribution of fatty and fibrous plaques in human coronary arteries
58. Localization of early atherosclerotic lesions in the arterial bifurcation in humans
59. Pulsatile flow and atherosclerosis in human carotid bifurcation: positive correlation between plaque location and low and oscillatory shear stress
60. Blood flow near the arterial wall and arterial disease
61. Effect of blood flow rale on subendothelial proliferation in venous autografts used as arterial substitutes
62. Local effects of stenoses: increased flow velocity inhibits atherogenesis
63. The proliferation of subconfluent endothelial cell room-layers exposed to shear stress (abstr)
64. The effect of fluid shear stress on the migration and proliferation of cultured endolhelial cells
65. Thrombin-elicited contractile responses of aortic smooth muscle cells
66. Selective immobilization of alpha-thrombin by surface-bound fibrin
67. Thrombin-stimulated events in cultured vascular smooth muscle cells
68. Thrombin interactions with cultured fibroblasts: relationship to mitogenic stimulation
69. Thrombin activation of the Na/H exchanger in vascular smooth muscle cells: evidence for a kinase C-independent pathway which is Ca dependent and pertussis toxinsensitive
70. Antiplatelet agents are effective in reducing the immediate complications of PTCA: resulls from the Ticlopidine Multicenter Trial (abstr)
71. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
72. A randomized trial of aspirin in PTCA: effect of high vs low dose aspirin on major complications and restenosis (abstr)
73. Effect of high dose and low dose aspirin on restenosis after primary successful angioplasty (abstr)
74. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study
75. Neither ticlopidine nor aspirin-dipyridamole prevent restenosispost-PTCA: results from a randomized piacebo-controlled multicenter trial (abstr)
76. Combined use of aspirin, ticlopidine and nicorandil prevented restenosis after coronary angioplasty (abstr)
77. Beneficial effects of ciprostene in PTCA: a multicenter. randomized controlled trial (abstrl
78. Prostaglandin El infusion after angioplasty in humans inhibits abrupt occlusion and early restenosis
79. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty
80. Fish oil improves endotheliumdependent relaxation in patients with coronary artery disease (abstr)
81. Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein
82. Inhibition of atherosclerosis by cod-liver oil in a hyperlipidemic swine model
83. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids
84. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty
85. Results of a randomized double-blind placebo-controlled trial of fish oil for prevention of restenosis after PTCA (abstr)
86. High dose omega-3-fatty acid supplement reduces clinical restenosis after coronary angioplasty (abstr)
87. Can oral fish oil supplement minimize restenosis after percutaneous transluminal coronary angioplasty? (abstr)
88. Vascular smooth muscle proliferation following balloon injury is synergistically inhibited by low molecular weight heparin and hydrocortisone (abstr)
89. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty
90. Short term, high dose steroid treatment to prevent restenosis in PTCA (abstr)
91. High-dose steroids for prevention ot recurrent restenosis post-PTCA: a randomized trial (abstr)
92. Very early prediction of restenosis after successful coronary angioplasty: anatomic and functional assessment
93. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty
94. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty
95. Ketanserin prevents acute occlusion but not restenosis after PTCA (abstr)
96. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and restenosis in the baboon
97. A monoclonal antibody to the platelet receptor GPIIb/IIIa prevents acute thrombus in a canine model of coronary angioplasty (abstr)
98. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
99. Phase I human trial of the potent anti-platelet agent 7E3-F(ab′)2. a monoclonal antibody to the GPIIb/IIIa receptor (abstr)
100. Inhibition of thrombus formation: blockage of adhesive glycoprotein mechanisms versus blockage of the cyclooxygenase pathway (abstr)
101. Effects of thrombin inhibition on the development of acute plateletthrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor
102. Hirudin, heparin, and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis
103. Permanent interruption of thrombin formation on carotid endarterectomy sites by short term therapy with a synthetic antithrombin (abstr)
104. Prevention of arterial platelet occlusion by selective thrombin inhibition (abstr)
105. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
106. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury
107. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk